Evaluation of cleaved caspase-3 and Ki-67 index on diagnostic biopsy in response to neoadjuvant chemotherapy in the context of post-treatment tumour ypT stage, ypN stage, grade, and molecular subtype.
Ki-67
breast cancer
cleaved caspase-3
diagnostic biopsy of breast cancer
neoadjuvant chemotherapy
prognostic biomarkers
Journal
Przeglad menopauzalny = Menopause review
ISSN: 1643-8876
Titre abrégé: Prz Menopauzalny
Pays: Poland
ID NLM: 101263235
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
12
12
2023
accepted:
01
02
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
1
5
2024
Statut:
ppublish
Résumé
Breast carcinoma is a heterogeneous disease, characterised by diverse clinical behaviour. The aim of this study was to assess how cleaved caspase-3 and Ki-67 index, evaluated on diagnostic biopsy, are related to response to neoadjuvant chemotherapy in the context of molecular subtype, post-treatment tumour, N category, and grade. A retrospective analysis was carried out among 110 breast cancer patients. Ki-67 levels and caspase-3 expression on diagnostic biopsy were explored regarding their relation to tumour grade and molecular subtype, ypT, ypN categories, and T and N categories according to Sataloff tumour response evaluation. A statistically significant relationship was found between Ki-67 levels and tumour grade K-W = 24.2932, No significant difference was found between Ki-67 expression in patients with pathological complete response, compared to those with partial and no response, a statistically significant difference in cases with different molecular subtype, histology grade, and tumour stage after neoadjuvant therapy. Cleaved caspase-3-positive breast cancer cases are often better responders to neoadjuvant therapy, but with no significant correlation to molecular subtype, high-grade categories, or tumour stage. The caspase-3 and Ki-67 index on diagnostic biopsy are related to post-neoadjuvant treatment prognostic factors (ypT stage, grade), proving them useful for prediction of treatment response to neoadjuvant therapy and further patient management.
Identifiants
pubmed: 38690065
doi: 10.5114/pm.2024.136962
pii: 52709
pmc: PMC11056723
doi:
Types de publication
Journal Article
Langues
eng
Pagination
31-40Informations de copyright
Copyright © 2023 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.